Publications by authors named "Lotta Ohm"

Claim this Profile
C
Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.
Torsten Dahlén, Gustaf Edgren, Mats Lambe, Martin Höglund, Magnus Björkholm, Lotta Ohm

Ann Intern Med· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib.
Lotta Ohm, Adam Lundqvist, Paul Dickman, Martin Höglund, Ulf Persson

Leuk Lymphoma· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Henrik Hjorth-Hansen, Leif Stenke, Stina Söderlund, Arta Dreimane, Hans Ehrencrona, Lotta Ohm

Eur J Haematol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.
Martin Höglund, Fredrik Sandin, Karin Hellström, Mats Björeman, Magnus Björkholm, Lotta Ohm

Blood· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome.
Lotta Ohm, Ingrid Arvidsson, Gisela Barbany, Robert Hast, Leif Stenke

Am J Hematol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
Bengt Simonsson, Tobias Gedde-Dahl, Berit Markevärn, Kari Remes, Jesper Stentoft, Lotta Ohm

Blood· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008.
Magnus Björkholm, Lotta Ohm, Sandra Eloranta, Asa Derolf, Malin Hultcrantz

J Clin Oncol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic myeloid leukemia presenting late in pregnancy. Report of a case and a questionnaire reflecting diversity in management options.
Magnus Björkholm, Lotta Ohm, Leif Stenke

Ann Hematol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical imatinib mesylate treatment induces early normalisation of aberrant neutrophil leukotriene C4 synthase expression and activity in chronic myeloid leukaemia.
Cecilia Roos, Leif Stenke, Lotta Ohm, Susanne Widell, Maria Kumlin

Br J Haematol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis